BioSpace News Archive

IN8bio, Inc. today announced April conference presentations: American Association for Cancer Research (AACR) Annual Meeting 2022 (New Orleans), April 8 – 13, 2022 Lawrence Lamb, Ph.D., CSO, will present “Maintenance-Phase Temozolomide as a Lymphodepletion Platform.

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing an investigational oral therapy Haduvio™ for pruritus in prurigo nodularis and chronic cough in idiopathic pulmonary fibrosis.

Coherus BioSciences, Inc., announced that effective March 31, 2022, the compensation committee of the Company’s board of directors granted options to purchase an aggregate of 461,000 shares of the common stock of the Company to newly hired employees with a per share exercise price of $12.91, the closing trading price on the grant date.

Organogenesis today announced that the latest advanced wound care research on its PuraPly® AM, Affinity®, Apligraf®, NuShield®, Novachor™ and Organogenesis Physician Solutions product lines will be showcased at the 2022 Symposium on Advanced Wound Care.

SELLAS Life Sciences Group, Inc. today provided a business update and overview of activity in the first quarter of 2022.

Newtopia Inc. today announced its fourth quarter and fiscal 2021 financial results, operational highlights and filing of its annual financial statements.

Puma Biotechnology, Inc., a biopharmaceutical company, announced that on April 1, 2022, the Compensation Committee of Puma’s Board of Directors approved the grant of inducement restricted stock unit awards covering 31,875 shares of Puma common stock to four new non-executive employees.

Lytix Biopharma AS notes that the first patient has been dosed in Verrica Pharmaceuticals Inc.'s Phase II study evaluating LTX-315 for the treatment of basal cell carcinoma (skin cancer).

Everest Medicines announced that the findings of reduction in proteinuria and stabilization of eGFR in a Chinese subpopulation after 9 months of treatment with NEFECON are in line with topline results from Part A of the pivotal global Phase 3 clinical trial NefIgArd, which were reported in November 2020 by Calliditas Therapeutics AB.

Kintor Pharmaceutical Limited announced the top-line results of the Phase III MRCT of proxalutamide in outpatients with mild to moderate COVID-19 regardless of vaccination status and risk factors.